Scientists reported that MRTX1133 treatment caused reversible growth arrest in KRASG12D-mutated colorectal cancer cells, accompanied by partial reactivation of RAS effector signaling.
[Oncogene]
Feedback Activation of EGFR/Wild-Type RAS Signaling Axis Limits KRASG12D Inhibitor Efficacy in KRASG12D-Mutated Colorectal Cancer
